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As a chronic inflammatory disorder of the skin, acne vulgaris affects almost 90% of adolescents, while an increasing number of adults are suffering from this disease. 1,2 Furthermore, with an accelerated onset of puberty, the prevalence is also showing a rising trend among children. 1 Besides the widespread use of conservative management protocols such as controlling dietary factors 3 and face-washing, 4 oral antibiotic therapy remains the first line of treatment for acne patients who are afflicted with physical and psychosocial side effects of moderate to severe forms of this skin condition. 5 Tetracyclines, including tetracycline, doxycycline, minocycline and lymecycline, as well as drugs like erythromycin, clindamycin, co-trimoxazole and trimethoprim have been shown to be effective oral agents. 6, 7 Macrolide antibiotics have a substantial cumulative effect in many tissues especially epithelial lining fluid and host defense cells, such as macrophages and polymorphonuclear leukocytes. 8 Macrolides share mild to moderate side effects such as nausea, vomiting, diarrhea, and abdominal pain, which are usually observed in erythromycin administration. 9 Azalides like azithromycin, as a class of macrolides, possess advantageous pharmacokinetic and pharmacodynamic properties compared to other macrolides. 9 Delivery to the infection site by phagocytes and fibroblasts results in higher concentration levels of the drug in tissues compared to serum level. 10, 11 This improves the safety and efficacy of azithromycin, which in turn not only reduces the dosage, but also decreases the frequency of drug use. 10, 11 Another pharmacological advantage of azithromycin is metabolization via hepatic pathways other than cytochrome P450, which lowers the risk of drug interactions. 10 A bioavailability of 37% after a single 500 mg oral dose and a half-life of 2.3 to 3.2 days depending on the tissues have been reported for azithromycin.
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Due to the remarkable pharmacokinetics and efficacy, azithromycin is well established as a potent treatment for skin infections in adult and pediatric patients. 12 In dermatology, clinical uses of azithromycin are not solely limited to infectious diseases. In addition to the antibacterial effects, due to the immunomodulatory and anti-inflammatory potentials of this agent, it appears that azithromycin can be administered to patients with dermatological disorders including intractable rosacea, 13-15 psoriasis 16, 17 and synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. [18] [19] [20] In this article, we reviewed the current clinical studies of azithromycin in the treatment of acne and discuss the tolerability and efficacy of this drug compared to other antibiotic options.
MATERIALS AND METHODS
The main keywords were "azithromycin" and "acne". English literature was searched for clinical trials using scientific search engines including Scopus and PubMed. No time limits were specified up to the date of the search (July 2018). A total of 22 articles, dating from 1994 to 2014 were found and full text of each paper was reviewed. These studies had predominantly focused on the dosage regimens, duration, and efficacy of oral azithromycin in the treatment of acne vulgaris.
RESULTS
Articles were summarized in Table 1 for easier comparison. The studies were conducted in various countries and differred in methodology. Study design, grouping, treatment dosage, duration and main results were described for each article.
DISCUSSION
For a long time, it has been believed that administration of macrolides such as azithromycin has anti-inflammatory effects. 43 In 2000, Ianaro et al. demonstrated that macrolides can suppress inflammation by inhibiting production of proinflammatory molecules such as PGE 2 , TNF-α, and NO x. 44 In addition, it has been observed that macrolides down-regulate neutrophil migration, ROS production and apoptosis. There is also growing evidence that macrolides, particularly azithromycin, exert immunomodulatory effects by diminishing production of IL-1α and IL-8 cytokines.
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Moreover, upregulated expression of proinflammatory factors such as IL-1α, TNF-α, PGE 2 , and IL-8 has been observed in acne patients. [46] [47] [48] [49] Thus, the therapeutic effects of azithromycin in acne vulgaris patients might be mediated by antimicrobial aspects of this agent as well as anti-inflammatory and immunomodulatory potentials. 50 Many studies focused on the comparison of azithromycin and doxycycline, suggesting significant improvement by using each of these medications with no remarkable differences in treatment results. [24] [25] [26] 28, 37, 40 However, the study by Ullah et al. on 386 patients showed that doxycycline was more effective. 21 In addition, Babaeinejad et al. concluded that doxycycline is more effective in patients above 18 years old. 26 It should also be noted that in both these studies, patients were treated with 4 consecutive days of 500 mg azithromycin per month; while it seems that intermittent higher doses, 24, 25, 39 mainly three times in 10-days or thriceweekly, may be more advantageous. Further, administration of azithromycin in combination with topical erythromycin results in significantly better improvement than doxycycline combined with topical erythromycin. 39 Also, no beneficial effects of minocycline were observed when compared to azithromycin. Open-label, randomized, 93 patients, 24 weeks 3 dosage regimens of azithromycin: Group 1: 4.5 g total dose in 7 weeks; Group 2: 6.0 g total dose in 10 weeks; Group 3: 7.5 g total dose in 13 weeks, A 3-day course of 500 mg/day followed by 500 mg/week for another 6 weeks in group 1, 9 weeks in group 2, and 12 weeks in group 3. Subjects were allowed to apply a keratolytic lotion topically twice a day.
Cure rate: 36.11% in group 1, 58.82% in group 2 and 55.88% in group 3. Azithromycin in a total dose of 6.0 g in 10 weeks was beneficial in the treatment of papulopustular acne with few side effects and good patient compliance. Ghoshal et al., 2007 (34) Randomized, 61 patients, 12 weeks Group 1: topical adapalene (0.1%) gel once daily at bedtime and 1 FTU for the entire face; Group 2: 500 mg oral azithromycin for 3 consecutive days in a week; Group 3: combination of the two therapies. Patients washed their face with soap for three to four times a day.
Although combination therapy showed highest reduction in the number of inflammatory lesions, there was no significant difference in the efficacy of the three treatment groups. Azithromycin response (84.7%) was slightly higher in reducing inflammatory lesions compared with tetracycline (79.7%). Similar rate of GI side effects (11%) were reported in both groups.
A study by Rafiei et al. found azithromycin to have a slightly higher efficacy in the treatment of inflammatory acne lesions in comparison to tetracycline. 36 On the other hand, retrospective study of patients who could not tolerate tetracycline, erythromycin, minocycline, and doxycycline proved that azithromycin is a significantly better antibiotic regimen for acne.
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Despite the usefulness of both isotretinoin and azithromycin in the treatment of moderate to severe acne, superior efficacy of isotretinoin is evident. 31 To enhance treatment outcome, various studies have utilized adjuvant drugs in combination therapies including topical tretinoin, adapalene, benzoyl peroxide and erythromycin. The combination of oral azithromycin with either topical adapalene 34 or oral levamisole 22 provided more efficacious treatment than azithromycin alone. In combination with isotretinoin, two studies have reported cure rates above 90%. 23, 27 Also, combined with adapalene plus benzoyl peroxidase, azithromycin was indicated as a safe option. 30 Considering azithromycin dosing for acne treatment, the most commonly used strategies are 3 consecutive days of 500 mg azithromycin in 10 days for 12 weeks, 25, 29, 39 azithromycin 500 mg three times per week for 8 22, 32 Retrospective, 79 patients, 10 weeks Individuals that were unable to tolerate tetracycline, erythromycin, minocycline, and doxycycline, were treated with azithromycin 250 mg three times a week. Most patients also used topical care.
Significant improvement was noted in 4 weeks in all agents, while azithromycin was significantly better with a greater than 80% reduction in inflammatory acne lesions (85.7%) vs. an average of 77.1% for all other agents. Gruber et al., 1998 (42) Open-label, 72 patients, 6 weeks Group 1: oral azithromycin 500 mg for 4 days every 10 days, for a total of four cycles; Group 2: minocycline 100 mg/day for 6 weeks 75.8% treatmentresponse with azithromycin and 70.5% with minocycline; Azithromycin was at least as effective as minocycline in the treatment of comedonic and papulopustular acne with well and similar tolerance.
In general, azithromycin was considered to be tolerable with low adverse effects including GI (namely nausea, diarrhea and abdominal pain) [29] [30] [31] [32] 35, 36 and CNS symptoms. 29 With regard to tetracycline induced photosensitivity, use of azithromycin may also be beneficial in summer months. 37 Low side effects and clinical tolerance along with convenient consumption have resulted in good patient compliance with azithromycin. 25, 28, 32, 35, [37] [38] [39] 41, 42 Various advantages have been suggested for azithromycin compared with other macrolides. There has always been a debate regarding the administration of antibiotics to pregnant and lactating patients due to possible side effects on fetus and infant. 51 In spite of the potential risks of azithromycin crossing placental barrier, no adverse effects have been observed in fetal development in animal models. Furthermore, FDA has classified azithromycin as a B category drug for treatment of acne vulgaris, confirming the compatibility of this drug with pregnancy. 51, 52 Although azithromycin has the longest halflife among macrolides and can be transferred to breast milk, it has not shown toxicity to fetus or infant. 53 Moreover, studies have indicated that administration of azithromycin to pregnant patients is as efficient as doxycycline in nonpregnant acne vulgaris patients. 37 Overall, these studies approved the use of azithromycin for the treatment of lactating or pregnant acne vulgaris patients.
Given the differences in azithromycin dosing and timing of administration, the conclusion on a specific effective therapeutic regimen for acne vulgaris remains indefinite. Nonetheless, most studies applied azithromycin thrice weekly or in 10 days with successful results. With regards to low incidence and mild side effects and also potential anti-inflammatory and immunomodulatory effects of azithromycin, this agent is a good choice for those who cannot tolerate other commonly used oral antibiotics. It is also important to consider that azithromycin is a safe drug for lactating and pregnant women suffering from acne vulgaris, making this drug a promising treatment. Furthermore, no resistance has been yet reported regarding treatment of acne vulgaris with azithromycin.
